Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Bodemer, Christine ^a   Guillet, Gerard ^b   Cambazard, Frederic ^c   Boralevi, Franck ^d   Ballarini, Stefania ^e   Milliet, Christian ^e   Bertuccio, Paola ^f   La Vecchia, Carlo ^f   Bach, Jean François ^a,g   De Prost, Yves ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e Vifor (International) Inc   (Switzerland)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LYSATE; CORTICOSTEROID; OM 85; PLACEBO; UNCLASSIFIED DRUG; BRONCHO-VAXOM; CELL EXTRACT; DERMATOLOGICAL AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ARTICLE; ATOPIC DERMATITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FAMILY HISTORY; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; UNSPECIFIED SIDE EFFECT; CHILD; DERMATITIS, ATOPIC; FEMALE; INFANT; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PREVALENCE; TREATMENT OUTCOME;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; CELL EXTRACTS; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; MALE; PREVALENCE; TREATMENT OUTCOME;

EID: 85016151158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161555     Document Type: Article

References (51)

1. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014; 71(1):116-32. https://doi.org/10.1016/j.jaad.2014.03.023 PMID: 24813302
2. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014; 71(2):327-49. PMID: 24813298
3. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014; 69 (1):3-16. https://doi.org/10.1111/all.12270 PMID: 24417229
4. Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: An update. Curr Opin Allergy Clin Immunol. 2013; 13(1):70-7. PMID: 23103806
5. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002; 347(12):911-20. https://doi.org/10.1056/NEJMra020100 PMID: 12239261
6. Figueiredo CA, Amorim LD, Alcantara-Neves NM, Matos SM, Cooper PJ, Rodrigues LC, et al. Environmental conditions, immunologic phenotypes, atopy, and asthma: new evidence of how the hygiene hypothesis operates in Latin America. J Allergy Clin Immunol. 2013; 131(4):1064-8, 1068 e1. https://doi.org/10.1016/j.jaci.2013.01.016 PMID: 23414599
7. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med. 2002; 8(6):625-9. https://doi.org/10.1038/nm0602-625 PMID: 12042815
8. Smit JJ, Van Loveren H, Hoekstra MO, Schijf MA, Folkerts G, Nijkamp FP. Mycobacterium vaccae administration during allergen sensitization or challenge suppresses asthmatic features. Clin Exp Allergy. 2003; 33(8):1083-9. PMID: 12911782
9. Sayers I, Severn W, Scanga CB, Hudson J, Le Gros G, Harper JL. Suppression of allergic airway disease using mycobacterial lipoglycans. J Allergy Clin Immunol. 2004; 114(2):302-9. https://doi.org/10.1016/j.jaci.2004.03.057 PMID: 15316507
10. Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleury S, Lazzari A, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011; 4(1):53-65. https://doi.org/10.1038/mi.2010.51 PMID: 20811345
11. Thorburn AN, Foster PS, Gibson PG, Hansbro PM. Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol. 2012; 188 (9):4611-20. https://doi.org/10.4049/jimmunol.1101299 PMID: 22461699
12. Donaldson DS, Apostolaki M, Bone HK, Richards CM, Williams NA. The Escherichia coli heat-labile enterotoxin B subunit protects from allergic airway disease development by inducing CD4+ regulatory T cells. Mucosal Immunol. 2013; 6(3):535-46. https://doi.org/10.1038/mi.2012.93 PMID: 23032791
13. Strickland DH, Judd S, Thomas JA, Larcombe AN, Sly PD, Holt PG. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol. 2011; 4(1):43-52. https://doi.org/10.1038/mi.2010.43 PMID: 20668438
14. Aumeunier A, Grela F, Ramadan A, Pham Van L, Bardel E, Gomez Alcala A, et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One. 2010; 5(7):e11484. https://doi.org/10.1371/journal.pone.0011484 PMID: 20628601
15. Han L, Zheng CP, Sun YQ, Xu G, Wen W, Fu QL. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014; 28(2):110-6. https://doi.org/10.2500/ajra.2013. 27.4021 PMID: 24717947
16. Ahrens B, Quarcoo D, Buhner S, Matricardi PM, Hamelmann E. Oral administration of bacterial lysates attenuates experimental food allergy. Int Arch Allergy Immunol. 2011; 156(2):196-204. https://doi.org/10.1159/000322352 PMID: 21597300
17. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes. 2006; 55(1):179-85. PMID: 16380491
18. Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: A phase 1 study. Mult Scler. 2011; 17(6):743-54. https://doi.org/10.1177/1352458511398054 PMID: 21372112
19. Rosche B, Wernecke KD, Ohlraun S, Dorr JM, Paul F. Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): Study protocol for a randomized controlled trial. Trials. 2013; 14:112. https://doi.org/10.1186/1745-6215-14-112 PMID: 23782752
20. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. Lancet. 2001; 357(9262):1076-9. https://doi. org/10.1016/S0140-6736(00)04259-8 PMID: 11297958
21. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003; 361(9372):1869-71. https://doi.org/10.1016/S0140-6736(03)13490-3 PMID: 12788576
22. Fiocchi A, Burks W, Bahna SL, Bielory L, Boyle RJ, Cocco R, et al. Clinical Use of Probiotics in Pediatric Allergy (CUPPA): A World Allergy Organization Position Paper. World Allergy Organ J. 2012; 5 (11):148-67. https://doi.org/10.1097/WOX.0b013e3182784ee0 PMID: 23282383
23. Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: A meta-analysis. Epidemiology. 2012; 23(3):402-14. PMID: 22441545
24. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol. 2003; 111(2):389- 95. PMID: 12589361
25. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;(4):CD006135. https://doi.org/10.1002/14651858.CD006135.pub2 PMID: 18843705
26. Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: A randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol. 2010; 11(5):351-61. https://doi.org/10.2165/11531420-000000000-00000 PMID: 20642296
27. Yang HJ, Min TK, Lee HW, Pyun BY. Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial. Allergy Asthma Immunol Res. 2014; 6(3):208-15. https://doi.org/10.4168/aair.2014.6.3.208 PMID: 24843795
28. Arkwright PD, David TJ. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br J Dermatol. 2003; 149(5):1029-34. PMID: 14632810
29. Gueniche A, Hennino A, Goujon C, Dahel K, Bastien P, Martin R, et al. Improvement of atopic dermatitis skin symptoms by Vitreoscilla filiformis bacterial extract. Eur J Dermatol. 2006; 16(4):380-4. PMID: 16935794
30. Berth-Jones J, Arkwright PD, Marasovic D, Savani N, Aldridge CR, Leech SN, et al. Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: A randomized, doubleblind, placebo-controlled trial. Clin Exp Allergy. 2006; 36(9):1115-21. https://doi.org/10.1111/j.1365- 2222.2006.02558.x PMID: 16961710
31. Brothers S, Asher MI, Jaksic M, Stewart AW. Effect of a Mycobacterium vaccae derivative on paediatric atopic dermatitis: A randomized, controlled trial. Clin Exp Dermatol. 2009; 34(7):770-5. https://doi.org/10.1111/j.1365-2230.2008.03153.x PMID: 19438539
32. Schaad UB, Mutterlein R, Goffin H, Group BV-CS. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: A double-blind, placebo-controlled multicenter study. Chest. 2002; 122(6):2042-9. PMID: 12475845
33. Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: A systematic review. World J Pediatr. 2010; 6(1):5-12. https://doi.org/10.1007/s12519-010-0001-x PMID: 20143206
34. Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357(9263):1191-4. PMID: 11323066
35. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008; 371(9609):281-3. https://doi.org/10.1016/S0140-6736(07)61835-2 PMID: 18221781
36. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994; 131(3):383-96. PMID: 7918015
37. Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP. Scoring the severity of atopic dermatitis: Three item severity score as a rough system for daily practice and as a prescreening tool for studies. Acta Derm Venereol. 1999; 79(5):356-9. PMID: 10494710
38. Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993; 186(1):23-31. PMID: 8435513
39. Andersen PK, Gill RD. Cox's Regression Model for Counting processes: A large sample study. Ann Statist. 1982; 10(4):1100-20
40. Kelly PJ, Lim LL. Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat Med. 2000; 19(1):13-33. PMID: 10623910
41. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000.
42. UCLA: Statistical Consulting Group. http://www.ats.ucla.edu/stat/sas/faq/survival-repeated-events. htm (accessed March 2014).
43. Sutton AJ, Abrams KA, Jones DR, Sheldon TA, Song F. Methods for Meta-analysis in Medical Research. Chichester: Wiley; 2000.
44. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol. 2001; 107(3):531-4. https://doi.org/10.1067/mai.2001.113081 PMID: 11240956
45. Davies MG, Symons C, Shaw S, Kaminski ER. An open study to assess the efficacy clinically and immunologically of M. vaccae vaccine in patients with atopic dermatitis. J Dermatolog Treat. 2006; 17 (2):74-7. https://doi.org/10.1080/09546630500515321 PMID: 16766329
46. Lau S, Gerhold K, Zimmermann K, Ockeloen CW, Rossberg S, Wagner P, et al. Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012; 129(4):1040-7. https://doi.org/10.1016/j.jaci.2012.02.005 PMID: 22464674
47. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989; 299(6710):1259-60. PMID: 2513902
48. Strachan DP. Family size, infection and atopy: The first decade of the "hygiene hypothesis". Thorax. 2000; 55 Suppl 1:S2-10.
49. Versalovic J. The human microbiome and probiotics: Implications for pediatrics. Ann Nutr Metab. 2013; 63 Suppl 2:42-52.
50. Isolauri E, Rautava S, Salminen S. Probiotics in the development and treatment of allergic disease. Gastroenterol Clin North Am. 2012; 41(4):747-62. https://doi.org/10.1016/j.gtc.2012.08.007 PMID: 23101685
51. Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol. 2013; 132 (3):601-7 e8. https://doi.org/10.1016/j.jaci.2013.05.043 PMID: 23900058